Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
JAMIA Open ; 5(3): ooac060, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2135373

ABSTRACT

Objective: In order to manage COVID-19 patient population and bed capacity issues, remote patient monitoring (RPM) is a strategy used to transition patients from inpatients to home. We describe our RPM implementation process for post-acute care COVID-19 pneumonia patients. We also evaluate the impact of RPM on patient outcomes, including hospital length of stay (LOS), post-discharge Emergency Department (ED) visits, and hospital readmission. Materials and Methods: We utilized a cloud-based RPM platform (Vivify Health) and a nurse-monitoring service (Global Medical Response) to enroll COVID-19 patients who required oxygen supplementation after hospital discharge. We evaluated patient participation, biometric alerts, and provider communication. We also assessed the program's impact by comparing RPM patient outcomes with a retrospective cohort of Control patients who similarly required oxygen supplementation after discharge but were not referred to the RPM program. Statistical analyses were performed to evaluate the 2 groups' demographic characteristics, hospital LOS, and readmission rates. Results: The RPM program enrolled 75 patients with respondents of a post-participation survey reporting high satisfaction with the program. Compared to the Control group (n = 150), which had similar demographics and baseline characteristics, the RPM group was associated with shorter hospital LOS (median 4.8 vs 6.1 days; P=.03) without adversely impacting return to the ED or readmission. Conclusion: We implemented a RPM program for post-acute discharged COVID-19 patients requiring oxygen supplementation. Our RPM program resulted in a shorter hospital LOS without adversely impacting quality outcomes for readmission rates and improved healthcare utilization by reducing the average LOS.

2.
JAMIA open ; 2022.
Article in English | EuropePMC | ID: covidwho-1940075

ABSTRACT

Objective In order to manage COVID-19 patient population and bed capacity issues, remote patient monitoring (RPM) is a strategy used to transition patients from inpatients to home. We describe our RPM implementation process for post-acute care COVID-19 pneumonia patients. We also evaluate the impact of RPM on patient outcomes, including hospital length of stay (LOS), post-discharge Emergency Department (ED) visits, and hospital readmission. >Materials and Methods We utilized a cloud-based RPM platform (Vivify Health) and a nurse-monitoring service (Global Medical Response) to enroll COVID-19 patients who required oxygen supplementation after hospital discharge. We evaluated patient participation, biometric alerts, and provider communication. We also assessed the program’s impact by comparing RPM patient outcomes with a retrospective cohort of Control patients who similarly required oxygen supplementation after discharge but were not referred to the RPM program. Statistical analyses were performed to evaluate the two groups’ demographic characteristics, hospital LOS, and readmission rates. Results The RPM program enrolled 75 patients with respondents of a post-participation survey reporting high satisfaction with the program. Compared to the Control group (n = 150), which had similar demographics and baseline characteristics, the RPM group was associated with shorter hospital LOS (median 4.8 vs 6.1 days;P =.03) without adversely impacting return to the ED or readmission. Conclusion We implemented a RPM program for post-acute discharged COVID-19 patients requiring oxygen supplementation. Our RPM program resulted in a shorter hospital LOS without adversely impacting quality outcomes for readmission rates and improved healthcare utilization by reducing the average LOS. LAY SUMMARY To improve hospital operations and bed utilization during the COVID-19 pandemic, we rapidly developed a remote patient monitoring (RPM) program as a strategy to facilitate the discharge of stable COVID-19 patients requiring supplemental oxygen and support their transition from the inpatient setting to home. We share our RPM implementation process and show that enrolled RPM patients were associated with shorter hospital length of stay (LOS) without any adverse impact on quality outcomes, such as return to the Emergency Department or readmission, compared to a cohort of control patients who were not enrolled in RPM. We also show that our RPM program had a high patient engagement rate and positive patient satisfaction. Our results demonstrate that RPM can be an essential part of the healthcare delivery model, as it could positively impact outcomes, healthcare utilization, and patient satisfaction.

4.
J Virol ; 94(24)2020 11 23.
Article in English | MEDLINE | ID: covidwho-941660

ABSTRACT

Intracranial (i.c.) infection of susceptible C57BL/6 mice with the neurotropic JHM strain of mouse hepatitis virus (JHMV) (a member of the Coronaviridae family) results in acute encephalomyelitis and viral persistence associated with an immune-mediated demyelinating disease. The present study was undertaken to better understand the molecular pathways evoked during innate and adaptive immune responses as well as the chronic demyelinating stage of disease in response to JHMV infection of the central nervous system (CNS). Using single-cell RNA sequencing analysis (scRNAseq) on flow-sorted CD45-positive (CD45+) cells enriched from brains and spinal cords of experimental mice, we demonstrate the heterogeneity of the immune response as determined by the presence of unique molecular signatures and pathways involved in effective antiviral host defense. Furthermore, we identify potential genes involved in contributing to demyelination as well as remyelination being expressed by both microglia and macrophages. Collectively, these findings emphasize the diversity of the immune responses and molecular networks at defined stages following viral infection of the CNS.IMPORTANCE Understanding the immunological mechanisms contributing to both host defense and disease following viral infection of the CNS is of critical importance given the increasing number of viruses that are capable of infecting and replicating within the nervous system. With this in mind, the present study was undertaken to evaluate the molecular signatures of immune cells within the CNS at defined times following infection with a neuroadapted murine coronavirus using scRNAseq. This approach has revealed that the immunological landscape is diverse, with numerous immune cell subsets expressing distinct mRNA expression profiles that are, in part, dictated by the stage of infection. In addition, these findings reveal new insight into cellular pathways contributing to control of viral replication as well as to neurologic disease.


Subject(s)
Central Nervous System Infections/immunology , Central Nervous System Infections/virology , Coronavirus Infections/immunology , Coronavirus Infections/virology , Host-Pathogen Interactions/immunology , Murine hepatitis virus/physiology , Animals , Central Nervous System Infections/genetics , Central Nervous System Infections/pathology , Computational Biology/methods , Coronavirus Infections/genetics , Coronavirus Infections/pathology , Encephalomyelitis/genetics , Encephalomyelitis/immunology , Encephalomyelitis/pathology , Encephalomyelitis/virology , Gene Expression Profiling , H-2 Antigens/genetics , H-2 Antigens/immunology , Host-Pathogen Interactions/genetics , Immunity, Innate , Mice , Sequence Analysis, RNA , Single-Cell Analysis
5.
Intell Based Med ; 3: 100009, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-885290

ABSTRACT

The COVID-19 pandemic has required greater minute-to-minute urgency of patient treatment in Intensive Care Units (ICUs), rendering the use of Randomized Controlled Trials (RCTs) too slow to be effective for treatment discovery. There is a need for agility in clinical research, and the use of data science to develop predictive models for patient treatment is a potential solution. However, rapidly developing predictive models in healthcare is challenging given the complexity of healthcare problems and the lack of regular interaction between data scientists and physicians. Data scientists can spend significant time working in isolation to build predictive models that may not be useful in clinical environments. We propose the use of an agile data science framework based on the Scrumban framework used in software development. Scrumban is an iterative framework, where in each iteration larger problems are broken down into simple do-able tasks for data scientists and physicians. The two sides collaborate closely in formulating clinical questions and developing and deploying predictive models into clinical settings. Physicians can provide feedback or new hypotheses given the performance of the model, and refinement of the model or clinical questions can take place in the next iteration. The rapid development of predictive models can now be achieved with increasing numbers of publicly available healthcare datasets and easily accessible cloud-based data science tools. What is truly needed are data scientist and physician partnerships ensuring close collaboration between the two sides in using these tools to develop clinically useful predictive models to meet the demands of the COVID-19 healthcare landscape.

6.
Glia ; 68(11): 2345-2360, 2020 11.
Article in English | MEDLINE | ID: covidwho-361267

ABSTRACT

The present study examines functional contributions of microglia in host defense, demyelination, and remyelination following infection of susceptible mice with a neurotropic coronavirus. Treatment with PLX5622, an inhibitor of colony stimulating factor 1 receptor (CSF1R) that efficiently depletes microglia, prior to infection of the central nervous system (CNS) with the neurotropic JHM strain of mouse hepatitis virus (JHMV) resulted in increased mortality compared with control mice that correlated with impaired control of viral replication. Single cell RNA sequencing (scRNASeq) of CD45+ cells isolated from the CNS revealed that PLX5622 treatment resulted in muted CD4+ T cell activation profile that was associated with decreased expression of transcripts encoding MHC class II and CD86 in macrophages but not dendritic cells. Evaluation of spinal cord demyelination revealed a marked increase in white matter damage in PLX5622-treated mice that corresponded with elevated expression of transcripts encoding disease-associated proteins Osteopontin (Spp1), Apolipoprotein E (Apoe), and Triggering receptor expressed on myeloid cells 2 (Trem2) that were enriched within macrophages. In addition, PLX5622 treatment dampened expression of Cystatin F (Cst7), Insulin growth factor 1 (Igf1), and lipoprotein lipase (Lpl) within macrophage populations which have been implicated in promoting repair of damaged nerve tissue and this was associated with impaired remyelination. Collectively, these findings argue that microglia tailor the CNS microenvironment to enhance control of coronavirus replication as well as dampen the severity of demyelination and influence repair.


Subject(s)
Brain/immunology , Coronavirus Infections/immunology , Host-Pathogen Interactions/immunology , Microglia/immunology , Murine hepatitis virus/immunology , Organic Chemicals/toxicity , Animals , Brain/drug effects , Brain/virology , Coronavirus Infections/chemically induced , Host-Pathogen Interactions/drug effects , Immunity, Cellular/drug effects , Immunity, Cellular/immunology , Male , Mice , Mice, Inbred C57BL , Microglia/drug effects , Microglia/virology
SELECTION OF CITATIONS
SEARCH DETAIL